Arcellx Announces Continued Robust Long-Term Responses From Its CART-ddBCMA Phase 1 Expansion Trial In Patients With Relapsed Or Refractory Multiple Myeloma At ASH
Portfolio Pulse from Benzinga Newsdesk
Arcellx, Inc. (NASDAQ: ACLX) reported positive long-term results from its Phase 1 expansion trial of anito-cel (CART-ddBCMA) for treating relapsed or refractory multiple myeloma. With a median follow-up of 26.5 months, the median duration of response, progression-free survival (PFS), and overall survival rate were not reached. The estimated median PFS is 28 months. The data will be presented at the ASH Annual Meeting on December 11, 2023. Anito-cel showed a 100% overall response rate, with 76% achieving complete response or stringent complete response. The treatment was well-tolerated with manageable adverse events. Arcellx plans to continue enrollment in the iMMagine-1 study and is preparing for commercial launch with partner Kite.
December 08, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcellx's positive trial results for anito-cel in treating multiple myeloma may boost investor confidence, potentially impacting the stock positively in the short term.
The positive clinical trial results for anito-cel suggest a strong potential for the drug's efficacy and safety in treating multiple myeloma, which is a significant unmet medical need. This could lead to increased investor optimism about the company's future prospects and potential revenue streams, especially given the Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the FDA. The news is highly relevant and important to Arcellx as it directly pertains to their lead product candidate. The confidence score reflects the robustness of the data and the clear positive impact it is likely to have on the company's valuation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100